CA2830939C - Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition - Google Patents
Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition Download PDFInfo
- Publication number
- CA2830939C CA2830939C CA2830939A CA2830939A CA2830939C CA 2830939 C CA2830939 C CA 2830939C CA 2830939 A CA2830939 A CA 2830939A CA 2830939 A CA2830939 A CA 2830939A CA 2830939 C CA2830939 C CA 2830939C
- Authority
- CA
- Canada
- Prior art keywords
- amyloid
- ch2x
- rph
- imaging
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58448704P | 2004-07-02 | 2004-07-02 | |
US60/584,487 | 2004-07-02 | ||
CA2587248A CA2587248C (en) | 2004-07-02 | 2005-07-01 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2587248A Division CA2587248C (en) | 2004-07-02 | 2005-07-01 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2830939A1 CA2830939A1 (en) | 2006-02-09 |
CA2830939C true CA2830939C (en) | 2017-02-28 |
Family
ID=35504952
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2830939A Active CA2830939C (en) | 2004-07-02 | 2005-07-01 | Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition |
CA2587248A Active CA2587248C (en) | 2004-07-02 | 2005-07-01 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2587248A Active CA2587248C (en) | 2004-07-02 | 2005-07-01 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
Country Status (16)
Country | Link |
---|---|
US (4) | US8147798B2 (pt-PT) |
EP (1) | EP1771208B1 (pt-PT) |
JP (1) | JP2008505115A (pt-PT) |
CN (2) | CN101137397A (pt-PT) |
AU (1) | AU2005270026A1 (pt-PT) |
BR (1) | BRPI0512893B8 (pt-PT) |
CA (2) | CA2830939C (pt-PT) |
CY (1) | CY1114644T1 (pt-PT) |
DK (1) | DK1771208T3 (pt-PT) |
ES (1) | ES2427963T3 (pt-PT) |
NO (1) | NO339187B1 (pt-PT) |
PL (1) | PL1771208T3 (pt-PT) |
PT (1) | PT1771208E (pt-PT) |
RU (1) | RU2007104107A (pt-PT) |
SI (1) | SI1771208T1 (pt-PT) |
WO (1) | WO2006014381A2 (pt-PT) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
GB0516564D0 (en) * | 2005-08-12 | 2005-09-21 | Ge Healthcare Ltd | Fluorination process |
WO2007035405A2 (en) * | 2005-09-16 | 2007-03-29 | University Of Pittsburgh | In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
CN101293878B (zh) * | 2007-04-25 | 2010-12-15 | 中国科学院上海应用物理研究所 | 苯并噻唑苯胺类化合物及其制备方法和应用 |
PL2182983T3 (pl) * | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
WO2009027452A2 (en) * | 2007-08-30 | 2009-03-05 | Ge Healthcare Limited | Radiopharmaceutical composition |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
JP5603855B2 (ja) | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク. | 神経変成疾患の放射性薬剤による画像化 |
RU2518892C2 (ru) * | 2008-09-23 | 2014-06-10 | Виста Лабораториз Лтд. | Лиганды для агрегированных молекул тау-белка |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010053218A1 (en) * | 2008-11-06 | 2010-05-14 | Snu R&Db Foundation | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
JP2013521233A (ja) * | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Aβを標的とする免疫療法のPETモニタリング |
WO2014004664A2 (en) * | 2012-06-27 | 2014-01-03 | Mayo Foundation For Medical Education And Research | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
AU2016308189B2 (en) * | 2015-08-18 | 2021-03-11 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
PL215711B1 (pl) * | 2000-08-24 | 2014-01-31 | Univ Pittsburgh | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
DE60217090T2 (de) * | 2001-04-23 | 2007-07-12 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel |
GB0130305D0 (en) | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
JP2005523903A (ja) | 2002-02-13 | 2005-08-11 | アメルシャム・パブリック・リミテッド・カンパニー | アミロイド斑の生体内撮像用のベンゾチアゾール誘導体 |
CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
GB0307855D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
BRPI0512932A (pt) * | 2004-07-02 | 2008-04-15 | Univ Pittsburgh | compostos e métodos de identificação e de diagnóstico de paciente como prodrÈmico para doença associada com a deposição amilóide |
-
2005
- 2005-07-01 PL PL05787557T patent/PL1771208T3/pl unknown
- 2005-07-01 WO PCT/US2005/023617 patent/WO2006014381A2/en active Application Filing
- 2005-07-01 DK DK05787557.7T patent/DK1771208T3/da active
- 2005-07-01 SI SI200531765T patent/SI1771208T1/sl unknown
- 2005-07-01 ES ES05787557T patent/ES2427963T3/es active Active
- 2005-07-01 CN CNA2005800263010A patent/CN101137397A/zh active Pending
- 2005-07-01 AU AU2005270026A patent/AU2005270026A1/en not_active Abandoned
- 2005-07-01 PT PT57875577T patent/PT1771208E/pt unknown
- 2005-07-01 US US11/666,083 patent/US8147798B2/en active Active
- 2005-07-01 CN CN2012104014697A patent/CN102973954A/zh active Pending
- 2005-07-01 JP JP2007519500A patent/JP2008505115A/ja active Pending
- 2005-07-01 CA CA2830939A patent/CA2830939C/en active Active
- 2005-07-01 EP EP05787557.7A patent/EP1771208B1/en active Active
- 2005-07-01 CA CA2587248A patent/CA2587248C/en active Active
- 2005-07-01 RU RU2007104107/04A patent/RU2007104107A/ru not_active Application Discontinuation
- 2005-07-01 BR BRPI0512893A patent/BRPI0512893B8/pt active IP Right Grant
-
2007
- 2007-01-31 NO NO20070593A patent/NO339187B1/no unknown
-
2012
- 2012-03-06 US US13/412,823 patent/US8343457B2/en active Active
- 2012-10-23 US US13/658,483 patent/US8580229B2/en active Active
-
2013
- 2013-09-10 CY CY20131100776T patent/CY1114644T1/el unknown
- 2013-10-09 US US14/050,018 patent/US20140105820A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SI1771208T1 (sl) | 2013-10-30 |
US20130045164A1 (en) | 2013-02-21 |
NO339187B1 (no) | 2016-11-14 |
CN102973954A (zh) | 2013-03-20 |
US20140105820A1 (en) | 2014-04-17 |
WO2006014381A2 (en) | 2006-02-09 |
ES2427963T3 (es) | 2013-11-05 |
CA2587248C (en) | 2014-01-07 |
EP1771208A2 (en) | 2007-04-11 |
US8343457B2 (en) | 2013-01-01 |
BRPI0512893A (pt) | 2008-04-15 |
RU2007104107A (ru) | 2008-08-10 |
US8147798B2 (en) | 2012-04-03 |
NO20070593L (no) | 2007-03-27 |
WO2006014381A9 (en) | 2006-04-13 |
PT1771208E (pt) | 2013-09-24 |
WO2006014381A3 (en) | 2007-01-18 |
BRPI0512893B1 (pt) | 2019-12-24 |
CA2587248A1 (en) | 2006-02-09 |
DK1771208T3 (da) | 2013-09-02 |
CA2830939A1 (en) | 2006-02-09 |
CY1114644T1 (el) | 2016-10-05 |
PL1771208T3 (pl) | 2013-11-29 |
AU2005270026A1 (en) | 2006-02-09 |
US20080219931A1 (en) | 2008-09-11 |
EP1771208B1 (en) | 2013-06-19 |
BRPI0512893B8 (pt) | 2021-07-27 |
US8580229B2 (en) | 2013-11-12 |
US20120177572A1 (en) | 2012-07-12 |
JP2008505115A (ja) | 2008-02-21 |
CN101137397A (zh) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2830939C (en) | Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition | |
DK2264018T3 (en) | Thioflavin derivatives for use in diagnosis of Alzheimer's disease | |
AU2011200667B2 (en) | Benzothiazole derivative compounds, compositions and uses | |
AU2001286702A1 (en) | Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease | |
CA2587253A1 (en) | A method of diagnosing prodromal forms of diseases associated with amyloid deposition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20131024 |